Simon Holt

A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the UK

Simon Holt, Gianfilippo Bertelli, Ian M. Humphreys et al. · British Journal of Cancer · 2013 · 101 citations · Full text

Medicine, Oncology, Pharmacoeconomics +15

Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor–positive, human epidermal growth factor receptor 2–negative early-stage breast cancer

Joan Albanell, Christer Svedman, Joseph Gligorov et al. · European Journal of Cancer · 2016 · 74 citations · Full text

Medicine, Oncology, Breast Oncology +12

Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation

Pascal Gellert, Corrinne V. Segal, Qiong Gao et al. · Nature Communications · 2016 · 43 citations · Full text

Medicine, Molecular Genetics, Oncology +16

Therapeutic mammaplasty is a safe and effective alternative to mastectomy with or without immediate breast reconstruction

Shelley Potter, Adam Trickey, Tim Rattay et al. · British journal of surgery · 2020 · 39 citations · Full text

Medicine, Oncology, Surgery +14

Core biopsy as a tool in planning the management of invasive breast cancer

Amar Deshpande, T Garud, Simon Holt · World Journal of Surgical Oncology · 2005 · 35 citations · Full text

Medicine, Oncology, Pathology +17